Ripamonti Ugo, Heliotis Manolis, Ferretti Carlo
Bone Research Unit, Medical Research Council/University of the Witwatersrand, Medical School, 2193 Parktown, Johannesburg, South Africa.
Oral Maxillofac Surg Clin North Am. 2007 Nov;19(4):575-89, vii. doi: 10.1016/j.coms.2007.07.006.
This article revisits the induction of bone by the osteogenic proteins of the transforming growth factor-beta superfamily in nonhuman and human primates and proposes that the translation in clinical contexts of the phenomenon of bone; formation by autoinduction, is predictably achievable by the binary application of relatively low doses of transforming growth factor-beta proteins with a recombinant human osteogenic protein. The synergistic induction of bone formation is a cost-effective clinical strategy because published data in nonhuman primates have shown that doses of recombinant human recombinant osteogenic protein-1 can be reduced at least fivefold and still increase bone formation compared with higher doses of single applications of human recombinant osteogenic protein-1.
本文重新审视了转化生长因子-β超家族的成骨蛋白在非人类和人类灵长类动物中诱导骨形成的情况，并提出在临床环境中通过自动诱导实现骨形成现象的转化，可通过将相对低剂量的转化生长因子-β蛋白与重组人成骨蛋白二元应用来实现。骨形成的协同诱导是一种具有成本效益的临床策略，因为在非人类灵长类动物中的已发表数据表明，与高剂量单次应用重组人成骨蛋白-1相比，重组人成骨蛋白-1的剂量可降低至少五倍，且仍能增加骨形成。
